Rice University engineers have achieved a remarkable feat in medical technology by developing the smallest implantable brain stimulator ever demonstrated in a human patient. This groundbreaking device, dubbed the Digitally Programmable Over-brain Therapeutic (DOT), operates wirelessly through an external transmitter and can stimulate the brain through the dura, the protective membrane attached to the skull’s bottom. With potential applications in treating drug-resistant depression and various psychiatric or neurological disorders, the DOT offers patients greater autonomy and accessibility compared to existing neurostimulation methods while also being less invasive than traditional brain-computer interfaces (BCIs).

The DOT, measuring a mere 9 millimeters in width, represents a significant departure from conventional implantable technologies, doing away with the need for bulky batteries and lengthy wires. Instead, it harnesses magnetoelectric power transfer technology to efficiently convert magnetic fields into electrical pulses, enabling precise stimulation of targeted brain areas. This innovation not only reduces the risk of hardware-related complications but also streamlines the implantation process, which is minimally invasive and leaves virtually no visible traces.

In recent trials, the DOT has demonstrated its efficacy in activating the motor cortex, eliciting hand movements in patients. Moreover, its stability in interfacing with the brain for extended periods, as evidenced by successful 30-day trials in both human and animal models, underscores its potential for widespread adoption. Lead researcher Jacob Robinson envisions the DOT being used in the comfort of patients’ homes, where they can administer treatments at their convenience, underlining its potential to revolutionize mental health care.

Looking ahead, researchers aim to further refine the DOT technology, exploring the development of implant networks for personalized therapies tailored to individual brain signatures. Motif Neurotech, the startup behind the DOT, is actively seeking FDA approval for long-term clinical trials in humans. Patients and caregivers interested in participating in these trials can stay informed through updates on the Motif Neurotech website, signalling a promising future for this groundbreaking medical innovation.

Follow Neureads for more.